Appendix B. Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group (LRiG):

  • Bagust A et al Pemetrexed for the treatment of relapsed non-small cell lung cancer, September 2006.

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope. Organisations listed in I were also invited to make written submissions. Organisations listed in II gave their expert views on pemetrexed by providing a written statement to the Committee. Organisations listed in I and II have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor

  • Eli Lilly and Company Ltd.

II) Professional/specialist and patient/carer groups:

  • British Thoracic Oncology Group

  • British Thoracic Society

  • Cancer Networks Pharmacists Forum

  • Cancer Research UK

  • CancerBackup

  • Department of Health

  • Roy Castle Lung Cancer Foundation

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians, Medical Oncology Joint Special Committee

  • Tenovus Cancer Information Centre

  • Welsh Assembly Government

III) Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • British Thoracic Oncology Group

  • MRC CTU - Lung Cancer and Mesothelioma Group

  • National Collaborating Centre for Cancer

  • NHS Quality Improvement Scotland

  • Roche Products Ltd.

  • Sanofi-Aventis

C. The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on pemetrexed by providing oral evidence to the Committee.

  • Dr Jesme Baird, Director of Patient Care, nominated by the Roy Castle Lung Cancer Foundation – patient expert

  • Professor David R Ferry, Medical Oncologist, New Cross Hospital, Wolverhampton, nominated by the Royal College of Physicians – clinical specialist

  • Dr Mary O'Brien, Consultant Medical Oncologist, Institute of Cancer Research, nominated by the Institute of Cancer Research – clinical specialist

  • Dr Elizabeth Sawicka, Consultant, Princess Royal University Hospital, nominated by The British Thoracic Society – clinical specialist